SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

Rosen Law Firm is soliciting lead plaintiffs for a securities fraud class action against ARS Pharmaceuticals (NASDAQ: SPRY), covering purchasers between March 9, 2026 and June 24, 2026, with an October 5, 2026 deadline to move the court. The suit alleges defendants made misleading statements about the expected timeline for expanded CVS Caremark insurance coverage of neffy, the company's epinephrine nasal spray, with coverage having been represented as starting July 1, 2026 in time for summer and back-to-school allergy seasons.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.